Medpace CEO Offloads $15.2M in Stock as CRO Shares Slip 4.2%
Medpace CEO August Troendle sold 24,376 shares for $15.2M across two late-September transactions, with MEDP dipping to $598.08. For health system and IT leaders tracking CRO capacity, insider selling adds a signal to watch alongside strong Q2 growth of 17.2%.